OptoSeeker Biotech and the National Major Science and Technology Infrastructure for Translational Medicine (Sichuan)/State Key Laboratory of Biotherapy at Sichuan University have officially launched a "Single-Cell Optofluidic Intelligent Screening Joint Demonstration Laboratory" in Chengdu. The partnership will leverage West China Hospital's clinical resources and OptoSeeker Biotech's high-throughput optofluidic single-cell screening technology to offer "end-to-end solutions" for antibody drug development, cell and gene therapy (CGT), and cell line development.
Leveraging Strengths to Address Industry Pain Points
This collaboration is based on a deep synergy between the partners' resources. OptoSeeker Biotech is an innovative life sciences instrument company focused on accelerating new drug discovery. Its proprietary single-cell functional screening platform can identify and isolate "seed" immune cells with the highest therapeutic potential from tens of thousands of cells. The company's core product, the
The National Major Science and Technology Infrastructure for Translational Medicine (Sichuan) is a key national research platform located in China's southwest region. It utilizes Sichuan University's interdisciplinary resources and the clinical expertise of West China Hospital to build a complete "technology chain" for biotherapy translational medicine research, covering everything from basic research to clinical applications.
By creating the joint laboratory, the partners will combine West China Hospital’s clinical resources with OptoSeeker Biotech’s technological advantages to offer "from cell screening to clinical translation" solutions. This will help solve industry challenges like low screening efficiency, a lack of precision, and poor integration with clinical translation.
The OptoBot® Platform's First Installation and Optimization
The National Major Science and Technology Infrastructure for Translational Medicine (Sichuan) is the first user to install the OptoBot® high-throughput optoelectric microfluidic cell screening platform. It will use its public R&D platform to expand the product's application scenarios and depth. By collecting data on screening efficiency, precision, and stability, the team will focus on real-world issues, such as compatibility for specific cell types (like B and T cells), ease of use, and software interface improvements. This feedback will be crucial for enhancing the product's hardware and software, helping it better meet the diverse needs of public R&D settings and accelerating its journey from the lab to industrial application.
Engineers Installing the OptoBot® High-Throughput Optoelectric Microfluidic Cell Screening Platform
Deepening Market Presence and Building an AI R&D Loop
For OptoSeeker Biotech, this partnership is a significant step toward expanding its presence in the southwestern life sciences market and better serving the region.
A key goal of the collaboration is to advance exploration in antibody discovery, cell line development, and cell and gene therapy. By using large-scale AI models for life sciences, the partners will analyze the vast amount of single-cell functional and sequencing data generated by the
Joint Laboratory Plaque Unveiling
Partnership Signing Ceremony
